ZA9883B - Liquid gonadotropin containing formulations - Google Patents

Liquid gonadotropin containing formulations

Info

Publication number
ZA9883B
ZA9883B ZA9883A ZA9883A ZA9883B ZA 9883 B ZA9883 B ZA 9883B ZA 9883 A ZA9883 A ZA 9883A ZA 9883 A ZA9883 A ZA 9883A ZA 9883 B ZA9883 B ZA 9883B
Authority
ZA
South Africa
Prior art keywords
containing formulations
liquid gonadotropin
gonadotropin containing
liquid
formulations
Prior art date
Application number
ZA9883A
Other languages
English (en)
Inventor
Arnold Titus Philip Skrabanja
Petrus Johannes Maria Oetelaar
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of ZA9883B publication Critical patent/ZA9883B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA9883A 1997-01-15 1998-01-06 Liquid gonadotropin containing formulations ZA9883B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97200099 1997-01-15

Publications (1)

Publication Number Publication Date
ZA9883B true ZA9883B (en) 1998-07-08

Family

ID=8227932

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9883A ZA9883B (en) 1997-01-15 1998-01-06 Liquid gonadotropin containing formulations

Country Status (30)

Country Link
US (1) US5929028A (ko)
EP (2) EP1285665A1 (ko)
JP (1) JP4353549B2 (ko)
KR (1) KR100498531B1 (ko)
CN (1) CN1165341C (ko)
AR (1) AR011410A1 (ko)
AT (1) ATE237348T1 (ko)
AU (1) AU736339B2 (ko)
BR (1) BR9800323B1 (ko)
CA (1) CA2226803A1 (ko)
CZ (1) CZ297419B6 (ko)
DE (2) DE69813322T2 (ko)
DK (1) DK0853945T3 (ko)
ES (1) ES2196474T3 (ko)
FR (1) FR10C0024I2 (ko)
HK (1) HK1010150A1 (ko)
HU (1) HU227154B1 (ko)
ID (1) ID19499A (ko)
IL (1) IL122732A0 (ko)
LU (1) LU91655I2 (ko)
MX (1) MX9800438A (ko)
NO (3) NO322509B1 (ko)
NZ (1) NZ329572A (ko)
PL (1) PL190103B1 (ko)
PT (1) PT853945E (ko)
RU (1) RU2203086C2 (ko)
SA (1) SA98181124B1 (ko)
TR (1) TR199800062A2 (ko)
TW (1) TW518235B (ko)
ZA (1) ZA9883B (ko)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004913A1 (en) * 1998-07-23 2000-02-03 Eli Lilly And Company Fsh and fsh variant formulations, products and methods
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
JP2007204498A (ja) * 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
CA2378949C (en) * 1999-07-12 2015-03-31 Grandis Biotech Gmbh Growth hormone formulations
IL151309A0 (en) * 2000-02-22 2003-04-10 Applied Research Systems Purification of lh and pharmaceutical compositions containing it
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
AU2007200662A1 (en) * 2001-08-30 2007-03-08 Kirin-Amgen, Inc. L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
EP1346843A1 (en) * 2002-03-22 2003-09-24 Fuji Photo Film Co., Ltd. Image forming method
EP1610803B8 (en) 2003-03-04 2011-09-14 AspenBio Pharma, Inc. LH for use in maintaining one or more pregnancies by inducing accessory corpus luteum formation.
AU2004226666B9 (en) * 2003-04-02 2010-04-08 Ares Trading S.A. Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
SI1638595T1 (sl) 2003-06-20 2013-04-30 Ares Trading S.A. Liofilizirane formulacije fsh/lh
JP4412989B2 (ja) * 2003-12-15 2010-02-10 株式会社日立製作所 複数の記憶システムを有するデータ処理システム
KR100587535B1 (ko) * 2004-02-04 2006-06-08 충남대학교산학협력단 재조합 ｈＦＳＨ 유전자 및 이를 내장하는 발현용 벡터
TWI369401B (en) * 2005-07-05 2012-08-01 Ares Trading Sa Serum-free culture medium for the production of recombinant gonadotropins
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
WO2007056851A1 (en) * 2005-11-17 2007-05-24 Mount Sinai Hospital Compositions and methods for enhancing ovulation inducing agents
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8450269B2 (en) * 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
WO2008038817A1 (en) * 2006-09-25 2008-04-03 National University Corporation Tokyo University Of Agriculture And Technology Ultrasonic operation device and microtube inside system
KR20080106636A (ko) * 2007-06-04 2008-12-09 동아제약주식회사 사람 융모성 성선자극호르몬 함유 즉시 사용형 주사 용액
WO2009002521A2 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
SI2170942T1 (sl) 2007-06-28 2013-12-31 Biogenerix Ag Produkcija celičnega klona folikle stimulirajočega hormona FSH
JP5551601B2 (ja) * 2007-11-01 2014-07-16 メルク セローノ ソシエテ アノニム Ｌｈ液体調製物
PL2249869T3 (pl) * 2008-02-08 2012-02-29 Theramex Hq Uk Ltd Ciekły preparat FSH
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
CN101347613B (zh) * 2008-09-17 2011-10-26 上海天伟生物制药有限公司 几乎不含亚基的糖蛋白的组合物及其制备方法
CN102309745B (zh) * 2008-09-17 2013-05-08 上海天伟生物制药有限公司 一种卵泡刺激素冻干针剂
ES2548378T3 (es) 2008-11-04 2015-10-16 Aska Pharmaceutical Co., Ltd. Composición acuosa que contiene hormona foliculoestimulante
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2325194A1 (en) 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012127501A2 (en) * 2011-03-11 2012-09-27 Sanzyme Limited Composition for improving endometrial thickness during ovarian stimulation
WO2012127500A2 (en) * 2011-03-11 2012-09-27 Sanzyme Limited Composition for spermatogenesis
WO2012131306A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
US20120265129A1 (en) 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
EP2734239A2 (en) 2011-07-18 2014-05-28 Arts Biologics A/S Long acting luteinizing hormone (lh) compound
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
EP2838552A4 (en) 2012-04-19 2016-05-18 Opko Biolog Ltd OXYNTOMODULIN VARIANTS WITH EXTENDED ACTION AND PROCESSES FOR PRODUCING SAME
BR112015008753A2 (pt) 2012-10-18 2017-07-04 Neuralight Hd Llc tratamento de depressão e ptsd
WO2014080401A2 (en) 2012-11-20 2014-05-30 Prolor Biotech Inc Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
ES2694328T3 (es) 2013-03-12 2018-12-19 Sumitomo Dainippon Pharma Co., Ltd. Composición acuosa líquida
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
JP6166470B2 (ja) 2013-11-12 2017-07-19 カディラ ヘルスケア リミティド ゴナドトロピンのための新規製剤
SG11201703184SA (en) * 2014-10-21 2017-05-30 Hexima Ltd A method of treatment
CN113289009A (zh) 2015-06-19 2021-08-24 Opko生物科学有限公司 长效凝固因子及其产生方法
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
CN118085104A (zh) 2016-07-11 2024-05-28 Opko生物科学有限公司 长效凝血因子及其制备方法
CN109803672A (zh) 2016-09-13 2019-05-24 阿勒根公司 稳定的非蛋白质梭菌毒素组合物
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
BR112021022860A2 (pt) 2019-05-16 2022-01-18 Ceva Sante Animale Composições e métodos para aumentar o desempenho da reprodução em mamíferos não humanos com uso de hormônio luteinizante recombinante
CN114404575A (zh) * 2020-12-07 2022-04-29 苏州智核生物医药科技有限公司 一种重组人促甲状腺素注射液

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357934A (en) * 1980-07-23 1982-11-09 The Curators Of The University Of Missouri Method of treating male infertility
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
IT1206302B (it) * 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
EP0461200B1 (en) * 1989-02-21 1997-01-22 Washington University Modified forms of reproductive hormones
US5338835A (en) * 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
US5114948A (en) * 1989-10-19 1992-05-19 Eli Lilly And Company Stabilized pergolide compositions
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
CA2133205C (en) * 1992-04-30 2007-04-17 Robert L. Swift Stable polypeptide composition
US5281198A (en) * 1992-05-04 1994-01-25 Habley Medical Technology Corporation Pharmaceutical component-mixing delivery assembly
BR9510567A (pt) * 1995-03-21 1998-06-23 Applied Research Systems Formulaçoes líquidas de hcg

Also Published As

Publication number Publication date
DE69813322T2 (de) 2004-02-19
CZ13598A3 (cs) 1998-08-12
ID19499A (id) 1998-07-16
DE69813322D1 (de) 2003-05-22
PL324279A1 (en) 1998-07-20
US5929028A (en) 1999-07-27
BR9800323A (pt) 1999-06-29
HUP9800056A3 (en) 2001-01-29
CZ297419B6 (cs) 2006-12-13
KR19980070493A (ko) 1998-10-26
HU227154B1 (en) 2010-08-30
DE122010000011I1 (de) 2010-07-08
JPH10203997A (ja) 1998-08-04
TW518235B (en) 2003-01-21
AU5205998A (en) 1998-07-23
HUP9800056A2 (hu) 1998-08-28
NO2010013I1 (no) 2010-06-07
NO2021001I1 (no) 2021-01-12
EP0853945A1 (en) 1998-07-22
KR100498531B1 (ko) 2005-09-30
HU9800056D0 (en) 1998-03-02
IL122732A0 (en) 1998-08-16
PT853945E (pt) 2003-08-29
CN1165341C (zh) 2004-09-08
NZ329572A (en) 1999-05-28
RU2203086C2 (ru) 2003-04-27
FR10C0024I1 (ko) 2010-05-21
NO2010013I2 (no) 2015-05-18
ATE237348T1 (de) 2003-05-15
BR9800323B1 (pt) 2011-04-19
EP0853945B1 (en) 2003-04-16
LU91655I2 (fr) 2010-04-26
NO980177D0 (no) 1998-01-14
PL190103B1 (pl) 2005-10-31
JP4353549B2 (ja) 2009-10-28
SA98181124B1 (ar) 2006-07-10
CN1191139A (zh) 1998-08-26
ES2196474T3 (es) 2003-12-16
MX9800438A (es) 1998-11-30
NO322509B1 (no) 2006-10-16
NO980177L (no) 1998-07-16
CA2226803A1 (en) 1998-07-15
TR199800062A2 (xx) 1998-08-21
HK1010150A1 (en) 1999-06-17
DK0853945T3 (da) 2003-08-04
FR10C0024I2 (fr) 2011-04-01
EP1285665A1 (en) 2003-02-26
AU736339B2 (en) 2001-07-26
AR011410A1 (es) 2000-08-16

Similar Documents

Publication Publication Date Title
HUP9800056A3 (en) Liquid gonadotropin containing formulations
HUP0000829A2 (en) Stable liquid interferon formulations
HUP9901893A3 (en) Novel stable liquid paracetamol compositions
IL135295A0 (en) 2-methyl-thieno-benzodiazepine formulation
HK1030813A1 (en) Liquid display
IL136937A0 (en) τ-GLUTAMYL AND β-ASPARTYL CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
PL325821A1 (en) Liquid acid netralising preparation
GB9817354D0 (en) Liquid formulation
IL133928A0 (en) Pharmaceutical composition containing peptichemio
HUP0002982A3 (en) Liquid compositions comprising lamivudine
PL340555A1 (en) Preparations containing dissolved paroxetin
GB2321253B (en) Liquid detergent formulation
ZA9810773B (en) Revitalisation formulation
GB9706957D0 (en) Formulation
GB9719567D0 (en) Liquid dispenser
ZA963510B (en) New liquid formulations
GB9816697D0 (en) Liquid formulations
GB2332913B (en) Liquid bleach composition
ZA989196B (en) Liquid compositions
HK1033088A1 (en) Liquid pharmaceutical formulation containing zotepine
SI1100328T1 (en) Liquid formulation
TW533790U (en) Elevating-type containing device
CA79809S (en) Liquid container
SI1054666T1 (en) Liquid pharmaceutical formulation containing zotepine
ZA974119B (en) Liquid fatty component containing composition